keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
Published 5 years ago • 425 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
7:56
keynote-048: progression post next line for r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
1:09
the future role of immunotherapy in head and neck cancers
-
1:52
dr. burtness on promise of frontline pembrolizumab in metastatic hnscc
-
3:22
keynote-224: pembrolizumab monotherapy for previously untreated hcc
-
5:48
the impact of systemic therapy and keynote-048 trial
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:18
keynote-048 trial
-
0:58
checkpoint inhibitors for head and neck cancer in the definitive setting?
-
1:55
dr. burtness on findings of keynote-048 in head and neck cancer
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer